

Immobilization of alpha toxin on the surface of the *Bacillus subtilis* spores

Amin Rostami^{1,2}, Fatemeh Goshadrou³, Nasim Rezaeinezhad², Mehdi Ghafari², Gholamreza Ahmadian²

¹Department of Basic Sciences, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

²Department of Industrial and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.

³Department of Physiology, School of Applied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

✉ **Reprint or Correspondence:** Gholamreza Ahmadian PhD, National Institute of Genetic Engineering and Biotechnology, Department of Industrial and Environmental Biotechnology, Tehran, Iran
✉ ahmadian@nigeb.ac.ir.

ABSTRACT

All strains of *Clostridium Perfringens* have gene encoding alpha toxin. Alpha toxin is important in pathogenesis of several diseases from gas gangrene to necrotic enteritis in chickens. The toxin consists of two domains, the N-domain containing the site for phospholipid hydrolysis and the C-domain plays a role in haemolytic and sphingomyelinase activities. The presence of the C-domain is crucial for recognition of the cell membrane phospholipids by the toxin. It is shown that immunization against the C-terminal domain of the toxin can make protection, at least partially against diseases like gas gangrene.

On the other hand, *Bacillus subtilis* spores are known to be GRAS, highly resistant to harsh conditions and inducing protective immune response. These attributes make *Bacillus subtilis* spores an ideal candidate for drug and vaccine delivery.

At the present study, as a preliminary step toward developing an effective vaccine against necrotic enteritis, the immunogenic region of alpha toxin is cloned, expressed and purified. The purified region was then covalently immobilized on the surface of the *Bacillus subtilis* spores, using non-genetically approach. The presence of alpha toxin on the spore surface is then verified by western blotting. In conclusion, C-terminal fragment of alpha toxin was successfully displayed on the spores of *Bacillus subtilis* using a non-genetically approach.

Keywords: alpha toxin, *Bacillus subtilis*, Immobilization.

Received: 16 June 2016 Accepted: 21 August 2016

Introduction

A wide range of experiments shows the role of alpha toxin from *Clostridium perfringens* (CP) in the pathogenesis of many diseases ranging from gas gangrene to several gastrointestinal diseases in human and animals (1-5). As the main toxin

produced by all types of CP, alpha toxin shows platelet aggregation, hemolysis effects on cells, contraction of blood vessels and phospholipase activity (6-8).

Immunization of mice with alpha-toxoid can protect them from gas gangrene (9). Vaccination of calves with the C-terminal domain of alpha toxin can partially protect them against bovine necrohemorrhagic enteritis (4). It is also shown that this toxin play an important role in pathogenesis of avian necrotic enteritis (NE) (10-12). NE costs more than 2 billion dollar a year for poultry industry worldwide (13). Furthermore it is claimed that alpha toxin is associated with some diseases like Crohn's disease (14). Some researchers also showed that sudden infant death syndrome (SIDS) is associated with alpha toxin in some cases (15, 16).

Alpha toxin consists of two domains; an N-terminal domain and a C-terminal domain (2). The former has phospholipase C activity on phosphatidylcholine (17) and the latter is essential in binding of the toxin to the membrane (6).

Substitution of Tyr-275, 307 and 331 residues by Asn, Phe, or Leu causes significant reduction in binding of the toxin to the membrane (18). Although the N-terminal domain of alpha toxin is enzymatically active in the absence of the C-domain, it has no hemolytic activity and toxic effects (17, 19). This confirm that binding of the alpha toxin to the target cell membrane is crucial for its cytotoxicity. This attachment is shown to be mediated through GPI-anchored proteins as the receptor (20).

On the other hand, displaying of recombinant proteins on the surface of bacterial cells and spores has drawn a lot of attention in biotechnology as a vaccine candidate (21, 22). In this context, special attention is given to the *Bacillus subtilis* spores. A number of reasons support the use of *Bacillus subtilis* spores as a suitable vaccine delivery vehicles. *Bacillus subtilis*

as well as its spores are known to be GRAS (Generally recognized as safe). *Bacillus* spores are highly resistant to the different harsh environmental conditions (23), can act as adjuvant (23) and can be used for delivery of heterologous proteins and vaccine candidates to the gastrointestinal tract (24).

In the present study, the immunogenic epitopes of alpha toxin was determined using bioinformatics tools. Then the selected part of the toxin was cloned, expressed in *E. coli* and purified. Finally, alpha toxin was attached to the surface of *Bacillus subtilis* spores non-genetically and surface immobilization was evaluated by western blotting.

Materials and Methods

Sequence analysis

Amino acid sequence of "Alpha toxin" (Acc. No. CAA35186.1) was obtained from GenBank. Antigenic properties was determined by submitting the toxin sequence into VAXIJEN software (<http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html>). The potential epitopic regions of the structure of the protein were predicted using BCPRED online tool (http://www.imtech.res.in/raghava/bcepred/bcepred_submission.html).

Cloning and protein expression

The selected part of the gene was synthesized at ShineGene Molecular Biotech, Inc (Shanghai, china). pUC57 plasmid harboring the recombinant gene was transformed into the competent *E. coli* DH5 α for amplification. The presence of the recombinant plasmid in the bacteria was confirmed by ampicillin selection and other control tests. The extracted pUC57 and pET-26b(+) plasmids were digested by NdeI and XhoI restriction enzymes. The approximately 351 bp

fragment was purified and inserted into the pET-26b (+) expression vector. Then plasmid was transformed into competent host *E. coli* BL21(DE3). Transformed bacteria were cultured in LB medium at 37 °C. After the OD₆₀₀ of bacterial culture reached 0.6-0.7, the expression of recombinant protein was induced by isopropylthio-β-D-galactoside (IPTG) at a final concentration of 1 mmol/L and then incubated for 5 hour at 30 °C. Finally, bacterial pellet was collected by centrifugation.

Protein purification

His-tagged recombinant protein was purified by Ni-NTA Magnetic Agarose Beads (QIAGEN Inc, USA). The bacterial pellet was suspended in lysis buffer (8 M Urea, 0.1 M NaH₂PO₄, 0.01 M Tris-Cl, 0.05% Tween 20, pH 8.0) and was shaken at room temperature for 1 Hour. The cell lysate was then centrifuged at 10000g for 30 min and the cleared supernatant was added to Ni-NTA resins. The suspension of resins and the cell lysate was incubated for 2 hour at room temperature, resins were washed 5 times with washing buffer (8 M Urea, 0.1 M NaH₂PO₄, 0.01 M Tris-Cl, 0.05%, imidazole 20 mM). At last, the recombinant protein was eluted by adding elution buffer containing (8M Urea, 0.1 M NaH₂PO₄, 0.01 M Tris-Cl, 0.05%, imidazole 250 mM). Protein samples were analyzed by SDS-PAGE analysis and western blotting.

Spore preparation and purification

Sporulation of *Bacillus subtilis* 168 *trpC2* was induced by the exhaustion method in Difco-Sporulation Medium (DSM). After sporulation, media containing spores were centrifuged at 10,000g, 20 min, 4°C. The pellet was treated with a solution containing MgSO₄ (2.5 µg/mL), lysozyme (200 µg/mL) and DNase I (2 µg/mL) for 30 min at 37 °C. In order to inactivate enzymes

and ensure the killing of vegetative cells, spores were then heat-treated at 68 °C for (45 min). After repeated washing steps with distilled water, purified spores were stored at -20 °C until use.

Immobilization on the surface of the spores

Covalent immobilization of the recombinant protein onto the *Bacillus* spore surface was performed as described previously (25). Briefly, functional groups of the spore surface was activated using glutaraldehyde. The solution of alpha toxin (100 µg.ml⁻¹) in 50 mM phosphate buffer (pH 7.5) was then added to the spores suspension at room temperature for 2 hour. Spores were harvested by centrifugation (4000 g, 10 min) and washed three times with 50 mM phosphate buffer (pH 7.5). A high concentration of salt solution (1 M NaCl) was used for washing of the suspension to eliminate non-covalently adsorbed recombinant proteins on the spore surface.

Spore decoating

Spore surface proteins including the recombinant protein were extracted by incubation of the manipulated spores in decoating extraction buffer (50 mM Tris-HCl (pH 8.0), 1 % (w/v) sodium dodecyl sulfate (SDS), 8 M urea, 50 mM dithiothreitol, 10 mM EDTA) for 90 min at 37 °C (26). The spore suspension was then centrifuged and the supernatant containing the recombinant protein was analyzed by SDS-PAGE and Western blotting to confirm the attachment of the recombinant protein onto to the spore surface.

SDS-PAGE and Western blot analysis

Extracted proteins were separated by SDS polyacrylamide gel electrophoresis (PAGE). Western blotting against the recombinant protein was carried out using a monoclonal anti-his tag antibody (Roche, USA). The recombinant protein

was separated on SDS-polyacrylamide gels and transferred to PVDF membrane (Roche, Germany). Further analysis was done according to the manufacturer instruction.

Results

Gene synthesis

A C-terminal region (amino acids number 256-370) of *Clostridium perfringens's* alpha toxin was selected for construction of gene expression cassette.

Prediction of mRNA structure

Folding of the mRNA for alpha toxin was predicted by mfold online software (<http://unafold.rna.albany.edu/>). As it is shown in figure 1, no long stable hairpin pseudoknot is observed at the initializing 5' nucleotides of the mRNA. The minimum free energy of the secondary structure formed by RNA was also

predicted as -86.8 kcal/mol.

B-cell epitopes

The sequence of the alpha toxin was submitted to VaxiGen online software while the cutoff value was set to 0.4 (Table 1). The selected region of the alpha toxin was predicted to be immunogenic. The epitopic regions were then mapped by BCPRED online service for alpha toxin.

Table 1. Scores of alpha toxin for being antigen

Toxin	Ag Score
Alpha Toxin	0.52
Alpha toxin (amino acids 256-370)	0.72

Protein expression and purification

E. coli BL21DE3 strain transformed with plasmid pET-AT was induced by IPTG at OD₆₀₀ 0.6. The recombinant Alpha toxin was extracted and purified by nickel beads according to the




Figure 1. mRNA stability analysis by mfold software.

manufacturer instruction (QIAGEN inc, USA, 2001). SDS PAGE 12% revealed a single band between molecular weight markers of 18.4 and 14.4 kDa were corresponds to the alpha toxin with the molecular weight of 15 kDa (Figure 2).




Figure 2. Visualization of the alpha toxin on SDS-PAGE.

Western blotting

To verify the attachment of recombinant alpha toxin on the spore surface, after treatment of the free and modified spores with decoating buffer, surface proteins were extracted from spore surface and were analyzed by SDS-PAGE and western blot analysis.

As it is shown in figure 3, western blot analysis using a monoclonal anti-his tag antibody (Roche, USA) showed a single band representing alpha toxin with approximate molecular weight of about 15 KDa was detected which is absent in the free spore surface extracted proteins.




Figure 3. Purification of the alpha toxin by Ni-NTA and further analyzing by western blotting. M: protein weight molecular marker, lane 1: un-induced total lysate of the *E. coli* bl21 (DE3), lane 2: western blotting of the purified alpha toxin.

Discussion

Alpha toxin plays an important role in pathogenesis of many diseases associated with *C. perfringens*. These include gas gangrene, necrotic enteritis, bovine necrohemorrhagic enteritis and Crohn's disease (4, 9, 10). It is shown that vaccination against C-terminal fragment of alpha toxin is effective against *C. perfringens* pathogenesis (3, 27).

The present study demonstrates the successful non-genetically immobilization of C-terminal domain of alpha toxin from *C. perfringens* on the surface of *Bacillus* spores. *Bacillus subtilis* is classified as a GRAS organism (generally recognized as safe). *Bacillus* spores benefit from some advantages including resistance to extreme temperatures, lytic enzymes and toxic chemicals, low cost maintenance and work as adjuvants. These features make spores an interesting platform

for delivery of drugs and vaccine candidates (28, 29).

As it is shown in Figure 1, the 5' terminus folding of mRNA is similar to the other bacterial gene folding structure. No long stable hairpin pseudoknot is observed at the initializing 5' nucleotides of the mRNA. The C-terminal domain of alpha toxin is seemed to be the antigenic part of the whole toxin as is predicted by bioinformatics tools (table 1). His-tagged truncated alpha toxin was successfully expressed in *E. coli* and purified using nickel beads (Figure 2). The purified alpha toxin is then immobilized on the surface of *Bacillus* spores using a glutaraldehyde. Washing of spores with high concentration of salt ensures that the attachment is carried out through just covalent immobilization on the surface of the spores. As indicated in Figure 3, western blot analysis of extracted spores surface proteins using a monoclonal anti-His antibody conjugated with HRP antibody confirm the presence of alpha toxin on the surface of the spores.

In recent years, many concerns raised globally toward using of GMO (Genetically Modified Organisms). As indicated here, the recombinant alpha toxin was attached onto the surface of spores as a live, safe carriers in a non-genetically approach. This approach for immobilization of drugs and vaccine candidates on the surface of spores can be used as a good alternative for DNA manipulated bacteria and spores surface display systems.

Conclusion

In conclusion, this is the first report describing covalent immobilization of alpha toxin on the

surface of *Bacillus subtilis* spores using a non-genetically approach.

Acknowledgement

This work has been supported by the center for international scientific studies & collaboration (CISSC).

Conflict of Interest

The authors declare no conflict of interest.

References

1. Nagahama M, Mukai M, Morimitsu S, Ochi S, Sakurai J. Role of the C-domain in the biological activities of Clostridium perfringens alpha-toxin. Microbiol Immunol 2002;46:647-55.
2. Naylor CE, Eaton JT, Howells A, Justin N, Moss DS, Titball RW, et al. Structure of the key toxin in gas gangrene. Nature 1998;5:738-46.
3. Zeng J, Deng G, Wang J, Zhou J, Liu X, Xie Q, et al. Potential protective immunogenicity of recombinant Clostridium perfringens α - β 2- β 1 fusion toxin in mice, sows and cows. Vaccine 2011;29:5459-66.
4. Goossens E, Verherstraeten S, Valgaeren BR, Pardon B, Timbermont L, Schauvliege S, et al. The C-terminal domain of Clostridium perfringens alpha toxin as a vaccine candidate against bovine necrohemorrhagic enteritis. Vet R 2016;47:52-3.
5. Hashiba M, Tomino A, Takenaka N, Hattori T, Kano H, Tsuda M, et al. Clostridium Perfringens Infection in a Febrile Patient with Severe Hemolytic Anemia. Am J Case Rep 2016;17:219-23.
6. Sakurai J, Nagahama M, Oda M. Clostridium perfringens alpha-toxin: characterization and mode of action. J Biochem 2004;136:569-74.
7. Titball RW, Naylor CE, Basak AK. The Clostridium perfringens alpha-toxin. Anaerob 1999;5:51-64.
8. Titball RW. Bacterial phospholipases C. Microbiol Rev 1993;57:347-66.
9. Williamson ED, Titball RW. A genetically engineered vaccine against the alpha-toxin of Clostridium perfringens protects mice against experimental gas gangrene. Vaccine 1993;11:1253-8.

10. Baba E, Fuller AL, Gilbert M, Thayer SG, McDougald LR. Effects of *Eimeria brunetti* and dietary zinc on experimental induction of necrotic enteritis in broiler chickens. *Avian Dis* 1992;36:59-62.
11. Cooper KK, Trinh HT, Songer JG. Immunization with recombinant alpha toxin partially protects broiler chicks against experimental challenge with *Clostridium perfringens*. *Vet Microbiol* 2009;133:92-7.
12. Lovland A, Kaldhusdal M, Redhead K, Skjerve E, Lillehaug A. Maternal vaccination against subclinical necrotic enteritis in broilers. *Avian Pathol* 2004;3:83-92.
13. Keyburn AL, Portela RW, Sproat K, Ford ME, Bannam TL, Yan X, et al. Vaccination with recombinant NetB toxin partially protects broiler chickens from necrotic enteritis. *Vet Res* 2013;44:54.
14. Gustafson C, Sjudahl R, Tagesson C. Phospholipase activation and arachidonic acid release in intestinal epithelial cells from patients with Crohn's disease. *Scandinavian journal of gastroenterology*. 1990;25(11):1151-60.
15. Murrell WG, Stewart BJ, O'Neill C, Siarakas S, Kariks S. Enterotoxigenic bacteria in the sudden infant death syndrome. *J Med Microbiol* 1993;39:114-27.
16. Siarakas S, Damas E, Murrell WG. The effect of enteric bacterial toxins on the catecholamine levels of the rabbit. *Pathology* 1997;29:278-85.
17. Titball RW, Leslie DL, Harvey S, Kelly D. Hemolytic and sphingomyelinase activities of *Clostridium perfringens* alpha-toxin are dependent on a domain homologous to that of an enzyme from the human arachidonic acid pathway. *Infect Immun* 1991;59:1872-74.
18. Alape-Giron A, Flores-Diaz M, Guillouard I, Naylor CE, Titball RW, Rucavado A, et al. Identification of residues critical for toxicity in *Clostridium perfringens* phospholipase C, the key toxin in gas gangrene. *Eur J Biochem* 2000;267:5191-97.
19. Nagahama M, Michiue K, Mukai M, Ochi S, Sakurai J. Mechanism of membrane damage by *Clostridium perfringens* alpha-toxin. *Microbiol Immune* 1998;42:533-38.
20. Gordon VM, Nelson KL, Buckley JT, Stevens VL, Tweten RK, Elwood PC, et al. *Clostridium septicum* alpha toxin uses glycosylphosphatidylinositol-anchored protein receptors. *J Biol Chem* 1999;274:27274-80.
21. Kim J, Schumann W. Display of proteins on *Bacillus subtilis* endospores. *Cell Mol Life Sci* 2009;66:3127-36.
22. Ciabattini A, Parigi R, Isticato R, Oggioni MR, Pozzi G. Oral priming of mice by recombinant spores of *Bacillus subtilis*. *Vaccine* 2004;22:4139-43.
23. Knecht LD, Pasini P, Daunert S. Bacterial spores as platforms for bioanalytical and biomedical applications. *Anal Bioanal Chem* 2011;400:977-89.
24. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. *Cell* 2004;118:229-41.
25. Ghaedmohammadi S, Rigi G, Zadmard R, Ricca E, Ahmadian G. Immobilization of Bioactive Protein A from *Staphylococcus aureus* (SpA) on the Surface of *Bacillus subtilis* Spores. *Mol Biotechnol* 2015;57:756-66.
26. Carroll AM, Plomp M, Malkin AJ, Setlow P. Protozoal digestion of coat-defective *Bacillus subtilis* spores produces "rinds" composed of insoluble coat protein. *Appl Environ Microbiol* 2008;74:5875-81.
27. Stevens DL, Titball RW, Jepson M, Bayer CR, Hayes-Schroer SM, Bryant AE. Immunization with the C-Domain of alpha -Toxin prevents lethal infection, localizes tissue injury, and promotes host response to challenge with *Clostridium perfringens*. *J Infect Dis* 2004;190:767-73.
28. Cutting SM, Hong HA, Baccigalupi L, Ricca E. Oral vaccine delivery by recombinant spore probiotics. *Int Rev Immunol* 2009;28:487-505.
29. Wang Y, Zhang Z. (Bacterial spore--a new vaccine vehicle--a review). *Wei Sheng Wu Xue Bao* 2008;48:413-17.